Medical Marijuana Inc (OTCMKTS:MJNA) reported that Axim Biotechnologies Inc (OTCMKTS:AXIM) has released a product pipeline chart on its site that focuses on the period from pre-clinical to a NDA for its various intellectual property-protected CBD-based products.
The product pipeline chart highlights what phase of clinical studies each drug of AXIM is in, the sign the medication is planned to cure and the projected date to get an NDA from the U.S. FDA and/or EMA. This chart also depicts the projected market launch date of the firm’s various functional nutraceutical and food products.
The management view
Dr. Stuart Titus, the CEO of Medical Marijuana, said that they praise AXIM Biotechnologies for issuing a product pipeline chart on its site as it offers potential investors and patients with critical firm data about the various CBD-based therapeutic offerings. These are the products that AXIM Biotechnologies presently has undergoing clinical studies and when those products are projected to be on the market and sanctioned by the EMA and FDA.
It’s thrilling to know the actual timelines for these CBD-based innovations in development, as the management is confident that once launched in the market, these unique therapeutics will offer customers with a wide variety of new alternatives worldwide.
An AXIM® breakthrough invention on stride to be fully listed by the FDA and EMA as soon as 2019 will be the globe’s first patented CBD controlled-release chewing gum named as MedChew Rx™. This chewing gum will transform the way that medicine is supplied to patients worldwide.
Talking about the other firm in the cannabis industry, Singlepoint Inc (OTCMKTS:SING) reported that its subsidiary is emerging from a quiet period to take benefit of amplified demand and legislative swings within the cannabis industry. This is because both sides politicians are pushing for resolutions to the marijuana banking conundrum on federal and state levels. Singlepoint’s board is confident that next week’s results will not disrupt unified measures to make way for enabling these firms to be bankable.
There is a rising need to look after business owners as legalization increases countrywide. Anderson Economic Group estimates that as many as seven states including Arizona, Maine, Nevada, Rhode Island, Vermont, Michigan and Missouri, are most likely to sanction cannabis by 2017.